International.
Demand for Evonik products rose worldwide in the first half of this year, the company said in an official statement.
"We have been able to increase volumes under persistently difficult business conditions," said Klaus Engel, Chairman of the Executive Board of Evonik Industries. "We are now confident that during the year we will deliver adjusted EBITDA in the upper average of the forecast range of €2 billion to €2.2 billion."
Evonik recorded considerable volume growth in the first six months of 2016, mainly as a result of growth in the second quarter. Despite higher volumes, the group's sales fell to €6,363 million, a decrease of 8% compared to the first half of 2015, mainly due to lower raw material costs being passed on to customers.
Adjusted EBITDA was also below the exceptionally strong figure of the previous period at €1.15 billion. Evonik again recorded a very good adjusted EBITDA margin of 18.1% in the first half of 2016.
Adjusted EBIT fell 18% to €795 million in the first six months. Adjusted net income decreased by 20% to €501 million. Net profit was €405 million, down 40% from the previous year's rising level, which contained the proceeds from the sale of the stake in Vivawest.
